Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types
出版年份 2019 全文链接
标题
Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types
作者
关键词
-
出版物
Cancers
Volume 11, Issue 3, Pages 354
出版商
MDPI AG
发表日期
2019-03-14
DOI
10.3390/cancers11030354
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Biomarkers for Homologous Recombination Deficiency in Cancer
- (2018) Michal M Hoppe et al. JNCI-Journal of the National Cancer Institute
- Biomarkers for Homologous Recombination Deficiency in Cancer
- (2018) Michal M Hoppe et al. JNCI-Journal of the National Cancer Institute
- Prediction of DNA Repair Inhibitor Response in Short Term Patient-Derived Ovarian Cancer Organoids
- (2018) Sarah J. Hill et al. Cancer Discovery
- Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history
- (2017) Kari G Chaffee et al. GENETICS IN MEDICINE
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes
- (2017) Nadeem Riaz et al. Nature Communications
- Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
- (2016) Yvette Drew et al. BRITISH JOURNAL OF CANCER
- Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer
- (2016) Suresh S. Ramalingam et al. CLINICAL CANCER RESEARCH
- Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity
- (2016) Rachel L. O’Donnell et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
- (2016) Jonathan A Ledermann et al. LANCET ONCOLOGY
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity
- (2015) Henning Willers et al. SEMINARS IN RADIATION ONCOLOGY
- A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer
- (2014) S. Novello et al. ANNALS OF ONCOLOGY
- Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules
- (2014) J Murray et al. BRITISH JOURNAL OF CANCER
- Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples
- (2014) M J Patterson et al. BRITISH JOURNAL OF CANCER
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- The Use of Ovarian Cancer Cells from Patients Undergoing Surgery to Generate Primary Cultures Capable of Undergoing Functional Analysis
- (2014) Rachel L. O′Donnell et al. PLoS One
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
- (2012) A. Mukhopadhyay et al. CANCER RESEARCH
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Sorafenib
- (2011) R. J. Kelly et al. CLINICAL CANCER RESEARCH
- Pancreatic cancer
- (2011) Audrey Vincent et al. LANCET
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
- (2011) A. G. Patel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) A. Mukhopadhyay et al. CLINICAL CANCER RESEARCH
- Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
- (2010) Yvette Drew et al. JNCI-Journal of the National Cancer Institute
- Correlations between RNA and protein expression profiles in 23 human cell lines
- (2009) Marcus Gry et al. BMC GENOMICS
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
- (2008) Alan Ashworth JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now